Antibody analyses
YFV, TBEV
VIRUS
Assessment of virus-specific IgG levels and nAbs against TBEV, JEV and/or YFV was performed on day 0, day 30, and at the final time-point of the clinical trial (day 210 for cohort A and cohort C, day 60 for B, D, and E). TBEV-specific IgG antibodies were assessed using an anti-TBE virus ELISA “Vienna” (IgG) kit (Euroimmun) and JEV-specific IgG antibodies were assessed using an anti-JEV ELISA (IgG) kit (Euroimmun) according to the manufacturer’s instructions. Both assays included complete virus lysates as coating antigen. Antibody levels equal to, or greater than, 120 were considered seropositive for TBEV-specific IgG and levels equal to, or greater than, 20 were considered seropositive of JEV-specific IgG, both as determined by the ELISA kit manufacturer. TBEV-specific IgG levels ≥1,000 Vienna units were recorded as 1,000 Vienna units and likewise, JEV-specific IgG levels ≥200 RU/ml were recorded as 200 RU/ml.Virus neutralization was measured by rapid fluorescent focus inhibition test (RFFIT) as previously described [